Previous 10 | Next 10 |
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announc...
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Mersana Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
Mersana Therapeutics, Inc. (MRSN) Q4 2021 Earnings Conference Call February 28, 2022, 08:00 AM ET Company Participants James Salierno - Associate Director, Investor Relations. Anna Protopapas - President & CEO Arvin Yang - Senior Vice President & Chief Medical Officer Brian DeSchuytne...
Mersana Therapeutics press release (NASDAQ:MRSN): Q4 GAAP EPS of -$0.68 misses by $0.01. As of December 31, 2021, the Company had cash and cash equivalents of $177.9 million For further details see: Mersana Therapeutics GAAP EPS of -$0.68 misses by $0.01,
Mersana Therapeutics press release (NASDAQ:MRSN): Q4 GAAP EPS of -$0.68 misses by $0.01. Revenue of $0.01M (-90.0% Y/Y) in-line. For further details see: Mersana Therapeutics GAAP EPS of -$0.68 misses by $0.01, revenue of $0.01M in-line
UPLIFT on track to complete enrollment Q3 2022, UP-NEXT to initiate in Q2 2022, and UPGRADE on track for 2H 2022 interim data readout XMT-1660 and XMT-2056 expected to enter clinic mid-2022 Research collaboration and license agreement with Janssen leverages Mersa...
Mersana Therapeutics (NASDAQ:MRSN) is scheduled to announce Q4 earnings results on Monday, February 28th, before market open. The consensus EPS Estimate is -$0.65 (-54.8% Y/Y) and the consensus Revenue Estimate is $0.01M (flat Y/Y). Over the last 3 months, EPS estimates have seen 1 upward rev...
AUPH, AZRE, BFLY, BRK.B, CVEO, CWEN, DEA, DQ, FREY, GLP, ITRI, JLL, KOS, LINC, MRSN, NLSN, PRTY, RETA, RIDE, TGNA, VRS, VTRS, XPEL, XRAY For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced...
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today an...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...